Medical Sciences Technology Corporation (MSTC) is a medical research company, focused on several important degenerative diseases HIV/AIDS, Chronic Heart Disease, certain types of Cancer, ARMD, and Diabetic Foot. To a lesser extent, the company is also a designer of innovative medical devices, and clinical health services. MSTC is focused in the field of conventional,[1]alternative & integrated medicine. MSTC has applied the business model concept of vertically integrated services, thereby applying its own research, its proprietary protocols, medical devices and clinical implementation that give it a leading edge in the healthcare industry. Through its Medical Consultants, MSTC is at the forefront for the treatment of HIV/AIDS, CHRONIC HEART DISEASE, ubiquitous ulcers, and numerous age-related and degenerative diseases.

Recently, the Company acquired the rights and title to the development of a new Auto-Vaccine for the treatment of HIV/AIDS. The protocols and designed medical devices were filed as Provisional Patents on the 13th of April 2009. The Company has improved the technology and will need to file a second patent to record the changes in the technology.


More than 60 million people have been infected with the human immunodeficiency virus since the beginning of the HIV/AIDS pandemic, and 2.7 million new HIV infections occurred in 2007 alone.  Cumulative deaths associated with HIV infection number more than 25 million, with 2.0 million occurring in 2007.  In the United States, more than 560,000 people with HIV/AIDS have died. More than 56,000 new HIV infections occur annually. Approximately 1.1 million people are living with the virus.   Source: National Institute for Allergy and Infectious Diseases

The hypothesis of an auto-vaccine for HIV is borne out by: 1) the present lack of a valid vaccine; 2) by a remarkable improvement of the HAART, which however does not prevent HIV mutagenicity and a consequent valid immunological response, and 3) the persistence of a hidden infection ready to thrive again. Firstly, by overcoming the variable antigenicity of HIV; secondly, by stimulating the immune system by the use of an adjuvant; thirdly, by directing the absorption of antigens via the lymphatic system and the simultaneous stimulation of heme-oxygenase-1, an auto-vaccine may alleviate the problem in many ways. The preparation of the auto-vaccine is described as well as the administration schedule, and a clinical study will define its validity.

Today, even the most advanced highly active anti-retroviral therapy (HAART), if it markedly improves survival, does not “cure” the human immunodeficiency virus (HIV) infection. By using the most varied HIV antigens, many vaccines have been prepared and tested with no results. This is partly due to the insufficient antigenicity, the inability of the immune system to mount a valid cell-mediated antibody response, and to the continuous viral mutations. On this basis, it is proposed that another strategy be adopted, consisting in counteracting every month the continuous antigenic variability with a new vaccine constituted by the modified viral particles present in the patient’s plasma. By directly treating the plasma with suitable ozone doses, both envelope and internal antigens will become exposed and partially oxidized, thus offering to antigen-presenting cells (APC) a variety of antigens, some of which can be elaborated and successively transferred to either specialized T-cytotoxic lymphocytes or/and B-lymphocytes for a subsequent antibody synthesis and secretion.

The crucial interaction of HIV antigens and immune cells will be enhanced in two ways: firstly by the addition of an immune adjuvant and secondly, and importantly, by diverting the absorption of the viral antigens towards the lymphatic system from the most varied subcutaneous sites of the body. This strategy will allow a far more consistent and prolonged interaction within several lymph nodes than the typical and single intramuscular administration of the vaccine. This methodological advantage was discovered by the inventor when, many years ago, he evaluated and made operative the intra-lymphatic administration of Interferons and Interleukin-2 able to profitably increase the biological activity of cytokines and reduce their toxicity. All of these original innovations are thought to be able to modify the course of the HIV infection and perhaps, with the simultaneous HAART, contribute to the eradication of the disease.


In 1983, after the discovery of the HIV, achievement of a vaccine was hoped for within two years. However, after 25 years of intensive and costly efforts by Health Authorities and Pharmaceuticals, there is no vaccine because this unique virus has an incredible genomic heterogeneity, undergoes frequent antigenic variations and is specialized in impairing the immune system leading to the acquired immune deficiency (AIDS). Baltimore [1] has recently voiced his pessimistic view for producing an effective vaccine to be proficiently used in different countries because there are conspicuous HIV variants in Asia and South-America. Fauci [2] has recently cancelled a new trial of a DNA plasmid vaccine and recommended the evaluation of new approaches. This situation is strikingly different from the successful polio and flu vaccines, to name a few serious diseases, which are now under control. Besides the actual availability of a dozen drugs, there is a constant search for novel therapeutic compounds able to hit HIV at multiple targets, such as either blocking the CCR5 molecular receptor or preventing the release of the virus from infected cells. Unfortunately all the time, the virus under the drug pressure, invents a new protein such as the virion infectivity factor [3] or HIV-1 accessory protein U [4] and is able to maintain HIV spreading. Although the constantly renewing highly active antiretroviral therapy (HAART) has remarkably improved the prognosis and prolonged survival, the infection remains with the possibility of a relapse owing to the development of a drug resistance and the risk of transmitting the disease to other subjects. Besides the millions of people already dead, one must consider the stressful and dispirited lives of some 33 million infected people worldwide. Moreover the socio-economical burden is a matter of grave concern and even more the fact that only less than one-third of the patients can undergo some form of therapy. The various ill-effects of intensive treatment that often reduce the compliance and the imperfect therapeutic results have also to be kept in mind. The HIV disease is especially harmful because the progressive destruction of the immune system prevents both the ability of forming specific antibodies and maintain an efficacious killer T cell activity [5,6]. This situation is conceptually dooming the vaccine proposal because, even assuming we produce an effective vaccine, unless we act at a very early stage, or we are able to restore the efficiency of the immune system, the vaccine cannot succeed in clearing the virus. Moreover the HIV, by quickly modifying its antigens, is always ready to evade any immunologic response and possibly accelerate the progress of the disease. Having now realized the presence of a high variability of HIV strains in different countries, the possibility of preparing a universal vaccine becomes a nightmare, if not altogether impossible.


[1] (CAIM also known as Complementary Alternative & Integrated Medicine).